Cargando…

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test

BACKGROUND: EndoPredict (EP) is a clinically validated multianalyte gene expression test to predict distant metastasis in ER-positive, HER2-negative breast cancer treated with endocrine therapy alone. The test is based on the combined analysis of 12 genes in formalin-fixed, paraffin-embedded (FFPE)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kronenwett, Ralf, Bohmann, Kerstin, Prinzler, Judith, Sinn, Bruno V, Haufe, Franziska, Roth, Claudia, Averdick, Manuela, Ropers, Tanja, Windbergs, Claudia, Brase, Jan C, Weber, Karsten E, Fisch, Karin, Müller, Berit M, Schmidt, Marcus, Filipits, Martin, Dubsky, Peter, Petry, Christoph, Dietel, Manfred, Denkert, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Technical Advance
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534340/ https://www.ncbi.nlm.nih.gov/pubmed/23039280 http://dx.doi.org/10.1186/1471-2407-12-456

Ejemplares similares

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections
por: Müller, Berit Maria, et al.
Publicado: (2012)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer
por: Poremba, Christopher, et al.
Publicado: (2014)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions
por: Müller, Berit Maria, et al.
Publicado: (2013)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
por: Martin, Miguel, et al.
Publicado: (2014)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis
por: Brase, Jan C., et al.
Publicado: (2013)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
por: Denkert, Carsten, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
por: Blank, Patricia R., et al.
Publicado: (2014)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Multianalyte Tests for the Early Detection of Cancer: Speedbumps and Barriers
por: Tainsky, Michael A., et al.
Publicado: (2007)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
por: Soliman, Hatem, et al.
Publicado: (2019)

Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence
por: Shore, Neal D, et al.
Publicado: (2012)

Early Cancer Detection from Multianalyte Blood Test Results
por: Wong, Ka-Chun, et al.
Publicado: (2019)

Rapid Multianalyte Microfluidic Homogeneous Immunoassay on Electrokinetically Driven Beads
por: Thiriet, Pierre-Emmanuel, et al.
Publicado: (2020)

Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer
por: Setayesh, Sonia Maryam, et al.
Publicado: (2022)

Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma
por: Firpo, Matthew A., et al.
Publicado: (2023)

Multianalytical Method Validation for Qualitative and Quantitative Analysis of Solvents of Abuse in Oral Fluid by HS-GC/MS
por: Coppe, Bruna Claudia, et al.
Publicado: (2016)

Effect of Diffusion Limitations on Multianalyte Determination from Biased Biosensor Response
por: Baronas, Romas, et al.
Publicado: (2014)

SERSbot: Revealing the Details of SERS Multianalyte Sensing Using Full Automation
por: Grys, David-Benjamin, et al.
Publicado: (2021)

A Multianalytical Approach for the Characterisation of Materials on Selected Artworks by Monogrammist IP
por: Šefců, Radka, et al.
Publicado: (2022)

Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women
por: Autelitano, Dominic J, et al.
Publicado: (2012)

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules
por: Liu, Quan‐Xing, et al.
Publicado: (2021)

Gold Mine Wooden Artefacts: Multianalytical Investigations for the Selection of Appropriate Consolidation Treatments
por: Fejfer, Mariusz, et al.
Publicado: (2022)

Performance of a Multianalyte ‘Rule-Out’ Assay in Pregnant Individuals With Suspected Preeclampsia
por: Costantine, Maged M., et al.
Publicado: (2022)

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
por: Wallace, Daniel J, et al.
Publicado: (2019)

Metabolic Discrimination of Select List Agents by Monitoring Cellular Responses in a Multianalyte Microphysiometer
por: Eklund, Sven E., et al.
Publicado: (2009)

Analytical performance of the automated multianalyte point-of-care mariPOC® for the detection of respiratory viruses
por: Sanbonmatsu-Gámez, Sara, et al.
Publicado: (2015)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cf1ca9g8qfmkat8eiopdocqnsj